advertisement
Kuwayama Y 10
Showing records 1 to 10 | Display all abstracts from Kuwayama Y98619 Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
Nakazawa T
Advances in Therapy 2022; 39: 1359-1374
98833 Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
Wirta DL
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 240-251
98619 Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
Takahashi K
Advances in Therapy 2022; 39: 1359-1374
98833 Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
Kuwayama Y
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 240-251
98619 Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
Kuwayama Y
Advances in Therapy 2022; 39: 1359-1374
98833 Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
Lu F
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 240-251
98619 Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
Nomura A
Advances in Therapy 2022; 39: 1359-1374
98833 Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
Shao H
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 240-251
98619 Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
Shimada F
Advances in Therapy 2022; 39: 1359-1374
98833 Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
Odani-Kawabata N
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 240-251
